<DOC>
	<DOCNO>NCT01500278</DOCNO>
	<brief_summary>This study conduct evaluate short ( 12 Weeks ) long term ( 104 Weeks ) efficacy Certolizumab Pegol compare Adalimumab combination Methotrexate ( MTX ) treatment moderate severe Rheumatoid Arthritis ( RA ) respond adequately MTX .</brief_summary>
	<brief_title>Study Assess Short- Long-term Efficacy Certolizumab Pegol Plus Methotrexate Compared Adalimumab Plus Methotrexate Subjects With Moderate Severe Rheumatoid Arthritis ( RA ) Inadequately Responding Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject must diagnosis Rheumatoid Arthritis ( RA ) Screening , define 2010 European League Against Rheumatism ( EULAR ) /American College Rheumatology ( ACR ) classification criterion ( Aletaha D et al , 2010 ) Subject must positive Rheumatoid Factor ( RF ) and/or positive antiCyclic Citrullinated Peptide antibody ( antiCCP ) determine central laboratory Screening Subject must moderate severe RA disease Screening Baseline define : 1 . Screening ( criterion require ) ≥ 4 swollen joint ( 28 prespecified joint ) Disease Activity Score [ Erythrocyte Sedimentation Rate ] ( DAS28 [ ESR ] ) &gt; 3.2 CReactive Protein ( CRP ) concentration ≥ 10 mg/L ( 1.0 mg/dL ) Erythrocyte Sedimentation Rate ( ESR ) ( Westergren ) ≥ 28 mm/hr 2 . Baseline ( criterion require ) ≥ 4 swollen joint ( 28 prespecified joint ) Disease Activity Score [ Erythrocyte Sedimentation Rate ] ( DAS28 [ ESR ] ) &gt; 3.2 Subject must inadequately respond previously Methotrexate ( MTX ) Subject use MTX 15 25 mg/week orally subcutaneously Screening use MTX regimen minimum 28 day prior Baseline Subject previously receive biological Disease Modifying Antirheumatic Drug ( DMARD ) receive treatment cyclophosphamide , chlorambucil , Janus Kinase , phosphodiesterase 4 inhibitor investigational agent spleen tyrosine kinase Diagnosis inflammatory arthritis Infected Tuberculosis ( TB ) high risk acquire TB infection Subjects concurrent acute chronic viral hepatitis B C infection Subjects history chronic recurrent infection subject high risk infection Use prohibit medication like nonbiological DMARDs ( exclude MTX ) , biological DMARDs exclude study medication , experimental therapy , IA hyaluronic acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Humira</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>